Federico Innocenti, MD, PhD

Associate Professor, UNC Eshelman School of Pharmacy

Associate Director for Oncology Research, UNC Institute for Pharmacogenomics and Individualized Therapy

919-966-9422   innocent@unc.edu
Publications Faculty Profile

Dr. Innocenti’s NIH-funded research program is currently focused on the discovery of genomic determinants of efficacy and toxicity of cancer chemotherapy, integrating clinical genomic investigation with functional evaluation of gene variation. MORE

Dylan Glubb, PhD

Postdoctoral Research Associate

919-966-9183   dylan.glubb@unc.edu
Publications Full biography

Dylan’s current research is focused on identifying functional germline genetic variants in the angiogenic VEGF-pathway for use as biomarkers of cancer outcome or anti-angiogenesis drug responses. He is also investigating the association of genetic variants with the mRNA and protein expression of important pharmacogenes in the human liver.

Dan Crona, PharmD

Graduate Student

crona@email.unc.edu

Dan’s translational research projects focus on the identification of genetic variants that associate with clinical endpoints, such as survival and toxicity. Specifically, Dan is focused on identifying functional germline variants in the angiogenesis pathway to help explain patient response to sorafenib in a renal cell carcinoma cohort. Dan is also involved with the identification of novel functional variants that associate survival outcomes in a cohort of patients with non-small cell lung cancer.

Zhen Hu, PhD

Postdoctoral Research Associate

huze@email.unc.edu

Zhen’s research is focused on assessing the functionality of genetic variants associated with pancreatic cancer outcomes through statistical analysis of data collected from lymphoblastoid cell lines and rodent models as well as clinical trials.  He is also involved in projects to identify functional germline genetic variants in oncogenic pathways for use as biomarkers of cancer outcomes or drug response.